Document is current
Any future updates will be listed below
-
Authors
Tsatsaris, Vassilis
Guibourdenche, Jean
Deneux-Tharaux, Catherine
,
Caretti, Natasha
Leguy, Marie-Clémence
Pace, Mathilde
Sentilhes, Loïc
Brossaud, Julie
Agnola, Marine
Guesquière, Louise
Renom, Gilles
Cacho, Isis
Blanc, Julie
Bretelle, Florence
Levy, Annie
Vacher, Justine
Morel, Olivier
Orlowski, Sophie
Hoffstetter, Marie
Letourneau, Alexandra
Lounis, Samra
Winer, Norbert
Masson, Damien
Vincke, Morgane
Berveiller, Paul
Annette-Reisch, Magali
Hot, Noémie
Verspyck, Eric
Girot, Hélène
Collins, Alexandra
Weingertner, Anne Sophie
Romain, Sarah
Le Mellec, Agate
Perrotin, Franck
Piver, Eric
Derrode, Marie Liesse
Kayem, Gilles
Meziati Boukhari, Sihame
Azria, Elie
Revel, Morgane
Gallot, Denis
Marceau, Geoffroy
Atallah, Antony
Pettazzoni, Magali
Leroux, Anne
Lecarpentier, Edouard
Redel, Diane
Le Lous, Maëla
Sault, Corinne
Guerby, Paul
Hamdi, Safouane
Duchanois, Delphine
Simon, Emmanuel
Lemaire, Stephanie
Godart, Sophie
Legendre, Guillaume
Moal, Valérie
Placais, Charline
Azimi, Shohreh
Abdoul, Hendy
Camara, Alice
Plence, Valérie
Buth-Guillemart, Victoria
Durand-Zaleski, Isabelle
Zarca, Kevin
Camilleri, Céline
Simons, Delphine
Seco, Aurelien
-
Funding
Funding for this research was provided by:
French Ministry of Health (National PHRC). (PHRC-20-0736)
- License Information
-
More Information
Article History
Received: 29 November 2025
Accepted: 4 March 2026
First Online: 20 March 2026
Declarations
:
: This research study was designed and is implemented in accordance with the Declaration of Helsinki’s principles on studies involving human subjects.RANSPRE trial was approved.- by the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) (national agency for drug safety), 23 May 2022.- by the following Approval Committee: Comité de Protection des Personnes (CPP South East III) (Committee for protection of persons involved in biomedical research), 16 April 2022.- by the Commission Nationale Informatique et Libertés (CNIL), 11 January 2023Informed written consent will be obtained from all participants.
: Not applicable.
: Vassilis Tsatsaris reports receiving lecture fees from Thermo Fisher Scientific, Roche Diagnostics, Sanofi and HAC Pharma. Paul Berveiller has participated in advisory board for Organon and Effik. Julie Blanc reports receiving lecture fees from Organon, Effik and Norgine. The other authors did not report any potential conflicts of interest.
